AHMAD UROLOGY LIMITED
Opportunity 72/100 (strong), bankability 75/100. High owner-dependency — earn-out structure likely required for clean transition. Share purchase looks the cleaner deal structure. Biggest value-creation lever: Cash flow review and working-capital discipline. Cash down -48% YoY — forensic review of receivables, stock turns, and creditor days. Most likely exit: strategic trade sale (65/100).
Data confidence
Overall: high (80/100)Strong data coverage across all sections. AI outputs should be trusted with minimal caveats.
Solid opportunity signal. Worth a dedicated memo and management meeting.
Signals from accounts
Derived from iXBRL accounts · accounting standard not declaredKey financials
2 years extracted from filed iXBRL accountsHover to see exact values · click legend to toggle series
Financials
Extracted from Companies House accounts · accounting standard unknown| Metric | 2025-03-31 | 2024-03-31 |
|---|---|---|
| Total assets | £742.2k | £645.0k |
| Current assets | £781.3k | £689.5k |
| Cash | £324.7k | £623.2k |
| Debtors | £456.6k | £66.2k |
| Net assets | £741.7k | £644.7k |
Amounts extracted automatically from iXBRL. Fields left blank were not reported or not mapped. Values in GBP unless stated.
1 signal detected in this company's narrative notes — going-concern language, audit opinion, contingent liabilities, related-party transactions.
Available from the Pro tier upwards.
See pricing →Recent activity
- • 1 accounts
- • 1 confirmation-statement
Corporate timeline (12 events)Click to expand
- 2025-12-04📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2024-12-02📄capital-allotment-sharescapital · SH01
- 2024-11-25📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2023-09-14📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2022-11-10📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2021-12-09📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2020-08-31📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2019-05-15📄change-account-reference-date-company-current-extendedaccounts · AA01
- 2018-11-14🏢Company incorporatedAs AHMAD UROLOGY LIMITED
- 2018-11-14➕AHMAD, Imran, Dr appointeddirector
- 2018-11-14➕HUSSAIN, Alliea Bibi appointeddirector
- 2018-11-14📄incorporation-companyincorporation · NEWINC
Owner dependency
Material founder dependency. Consider a 2-3 year earn-out and build in a handover plan before completion.
- +Two-director setup: Only two active directors — typical of owner-managed SMEs but limits succession.
- +Founder name in company name: Company name contains director surname "AHMAD" — strong identity link between founder and business.
- +No director turnover: Company is 7 years old with no director changes — suggests a very tight-knit founder team never broadened.
Succession & seller-readiness
Limited succession signal. Not a near-term off-market candidate.
- secondaryTwo-director governance: Small-team governance. Succession depth is thin but not absent.
Red flags
cleanShareholders & ownership
2 active beneficial owners| Name | Shares | Voting rights | Nature of control | Notified |
|---|---|---|---|---|
Dr Imran Ahmad Individual · British · DOB 07/1979 · age 47 | 25–50% | 25–50% | board control25-50% shares · 25-50% voting · board control | 14/11/2018 |
Mrs Alliea Bibi Hussain Individual · British · DOB 10/1982 · age 44 | 25–50% | 25–50% | board control25-50% shares · 25-50% voting · board control | 14/11/2018 |
From Companies House Persons with Significant Control filings. Share ranges are banded per the public PSC regime.
Radial SVG graph showing every company connected via shared directors, colour-coded by status.
Available from the Pro tier upwards.
See pricing →Similar companies
Active · Healthcare & medical · G postcode area| Company | Est. value | Turnover | Net worth | Staff | Age | Opp | Director |
|---|---|---|---|---|---|---|---|
| AM NURSERY GROUP LIMITED→ SC768675 · est 2023 · no financials extracted | — | — | — | — | 2y | — | — |
| AMARANTHINE AESTHETICS & WELLBEING LTD→ SC677484 · est 2020 · no financials extracted | — | — | — | — | 5y | — | — |
| AMD MAPLE LIMITED→ SC797976 · est 2024 · no financials extracted | — | — | — | — | 2y | — | — |
| AMIRS HEALTHCARE LIMITED→ SC633331 · est 2019 · no financials extracted | — | — | — | — | 6y | — | — |
| AMZPHARM LTD→ SC698191 · est 2021 · no financials extracted | — | — | — | — | 4y | — | — |
| AN KANG LTD→ SC842040 · est 2025 · no financials extracted | — | — | — | — | 1y | — | — |
| ANDERSON DOE PODIATRY CLINIC LIMITED→ SC641104 · est 2019 · no financials extracted | — | — | — | — | 6y | — | — |
| ANDREW BIANKIN LTD→ SC500006 · est 2015 · no financials extracted | — | — | — | — | 11y | — | — |
| ANGELA HECHT THERAPY LTD→ SC714674 · est 2021 · no financials extracted | — | — | — | — | 4y | — | — |
| ANGELIKI PAPADOPOULOU LTD→ SC755723 · est 2023 · no financials extracted | — | — | — | — | 3y | — | — |
| ANK ASSOCIATES & CO LTD→ SC852003 · est 2025 · no financials extracted | — | — | — | — | — | — | — |
| ANNE MORRISON HEALTH LTD→ SC854383 · est 2025 · no financials extracted | — | — | — | — | — | — | — |
6 specific questions generated from this company's actual signals — liquidity, leverage, director age, charge count, red flags, age-of-company.
Available from the Pro tier upwards.
See pricing →Exit-route ranking, improvement thesis, quiet-distress detector, covenant-pressure proxy, extraction monitor, approaching triggers, ownership drift, local cluster, value trap, debt capacity, archetype classification — 48+ scoring modules.
Available from the Pro tier upwards.
See pricing →Company details
Registered office
Filing status
Officers (2 active · 0 resigned)
Click a director name to see their full track record across all companies.